Scaglione-Sewell B A, Bissonnette M, Skarosi S, Abraham C, Brasitus T A
Department of Medicine, The University of Chicago, Illinois 60637, USA.
Endocrinology. 2000 Nov;141(11):3931-9. doi: 10.1210/endo.141.11.7782.
Previous studies by our laboratory have shown that a noncalcemic fluorinated analog of 1alpha,25-dihydroxyvitamin D3, 1alpha,25-dihydroxy-16-ene-23-yne-26,27-hexafluorocholcal ciferol (F6-D3), significantly reduced the frequency of colonic adenomas and completely abolished the development of colonic adenocarcinomas in rats treated with azoxymethane. The mechanisms involved in this analog's chemopreventive actions, however, remain unclear. In the present study, we now show that although both 1alpha,25-dihydroxyvitamin D3 and F6-D3 inhibited the proliferation of CaCo-2 cells, a human colonic adenocarcinoma cell line, by increasing their doubling times, only F6-D3 caused an arrest of these cells in the G1 phase of their cell cycle. This arrest was accompanied by an increase in the expression of the cyclin-dependent kinase (cdk) inhibitor proteins, p2Waf1 and p27Kip1, which served to decrease the activity of cyclin-dependent kinase 2 and cyclin-dependent kinase 6, whereas the expression and phosphorylation of pRB were unchanged. In contrast to the increased expression of these cdk inhibitors, the expression of cyclin E was decreased, which further inhibited the activity of cyclin-dependent kinase 2. Collectively, the inhibition of these cyclin-dependent kinases served to arrest the CaCo-2 cells, independent of changes in pRB. Furthermore, antibody neutralization studies suggest that transforming growth factor-beta may mediate the coassociations between cdk2 and p27Kip1 and cyclin E induced by F6-D3. These data indicate that cell cycle arrest may, at least in part, underlie the chemopreventive actions of F6-D3 observed in the azoxymethane model of colon cancer. Furthermore, if the antiproliferative action observed in CaCo-2 cells also occurs in human colonic epithelium, F6-D3 may have chemopreventive potential against human colon cancer, as well.
我们实验室之前的研究表明,1α,25-二羟基维生素D3的一种非钙调氟代类似物,1α,25-二羟基-16-烯-23-炔-26,27-六氟胆钙化醇(F6-D3),能显著降低用氧化偶氮甲烷处理的大鼠结肠腺瘤的发生率,并完全抑制结肠腺癌的发生。然而,这种类似物化学预防作用的机制仍不清楚。在本研究中,我们现在表明,虽然1α,25-二羟基维生素D3和F6-D3都通过延长其倍增时间来抑制人结肠腺癌细胞系CaCo-2细胞的增殖,但只有F6-D3能使这些细胞在细胞周期的G1期停滞。这种停滞伴随着细胞周期蛋白依赖性激酶(cdk)抑制蛋白p2Waf1和p27Kip1表达的增加,这有助于降低细胞周期蛋白依赖性激酶2和细胞周期蛋白依赖性激酶6的活性,而pRB的表达和磷酸化没有变化。与这些cdk抑制剂表达增加相反,细胞周期蛋白E的表达降低,这进一步抑制了细胞周期蛋白依赖性激酶2的活性。总的来说,这些细胞周期蛋白依赖性激酶的抑制作用使CaCo-2细胞停滞,与pRB的变化无关。此外,抗体中和研究表明,转化生长因子-β可能介导F6-D3诱导的cdk2与p27Kip1以及细胞周期蛋白E之间的相互关系。这些数据表明,细胞周期停滞可能至少部分是在氧化偶氮甲烷结肠癌模型中观察到的F6-D3化学预防作用的基础。此外,如果在CaCo-2细胞中观察到的抗增殖作用也发生在人结肠上皮细胞中,F6-D3可能也具有预防人类结肠癌的潜力。